Aprea Therapeutics Stock Performance
| APRE Stock | USD 0.67 0 0.45% |
The firm shows a Beta (market volatility) of 1.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aprea Therapeutics will likely underperform. At this point, Aprea Therapeutics has a negative expected return of -0.73%. Please make sure to confirm Aprea Therapeutics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Aprea Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Aprea Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:20 | Last Split Date 2023-02-13 |
1 | Will Aprea Therapeutics Inc. stock outperform value stocks - Quarterly Earnings Report Fast ExitEntry Strategy Plans - newser.com | 11/06/2025 |
2 | Aprea Therapeutics, Inc. Is Breakeven Near | 12/03/2025 |
3 | Aprea Therapeutics Announces 3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 12/09/2025 |
4 | Acquisition by Oren Gilad of 21459 shares of Aprea Therapeutics at 1.04 subject to Rule 16b-3 | 12/10/2025 |
5 | Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN | 12/12/2025 |
6 | Why retail investors favor Aprea Therapeutics Inc. stock - Trade Volume Report Free Reliable Trade Execution Plans - DonanmHaber | 12/19/2025 |
7 | Can Aprea Therapeutics Inc. stock weather global recession - Energy Sector Updates Small Budget Capital Investment - Bollywood Helpline | 12/23/2025 |
8 | Acquisition by Oren Gilad of 250 shares of Aprea Therapeutics at 2.9 subject to Rule 16b-3 | 12/26/2025 |
9 | Can Aprea Therapeutics Inc. stock reach 100 price target - 2025 Analyst Calls Daily Technical Stock Forecast Reports - ulpravda.ru | 01/08/2026 |
10 | Aprea Therapeutics Lowered to Strong Sell Rating by Zacks Research | 01/15/2026 |
11 | Aprea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView Track All Markets | 01/23/2026 |
12 | Acquisition by Peters Richard of 4185 shares of Aprea Therapeutics at 4.07 subject to Rule 16b-3 | 01/27/2026 |
13 | Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Part... | 01/29/2026 |
14 | Acquisition by Hamill John P. of 5700 shares of Aprea Therapeutics at 0.765 subject to Rule 16b-3 | 01/30/2026 |
| Begin Period Cash Flow | 21.6 M | |
| Total Cashflows From Investing Activities | -15.5 K |
Aprea Therapeutics Relative Risk vs. Return Landscape
If you would invest 120.00 in Aprea Therapeutics on November 6, 2025 and sell it today you would lose (52.70) from holding Aprea Therapeutics or give up 43.92% of portfolio value over 90 days. Aprea Therapeutics is currently does not generate positive expected returns and assumes 6.7232% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Aprea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aprea Therapeutics Target Price Odds to finish over Current Price
The tendency of Aprea Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.67 | 90 days | 0.67 | over 95.99 |
Based on a normal probability distribution, the odds of Aprea Therapeutics to move above the current price in 90 days from now is over 95.99 (This Aprea Therapeutics probability density function shows the probability of Aprea Stock to fall within a particular range of prices over 90 days) .
Aprea Therapeutics Price Density |
| Price |
Predictive Modules for Aprea Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aprea Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Aprea Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Aprea Therapeutics is not an exception. The market had few large corrections towards the Aprea Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aprea Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aprea Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.04 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 0.20 | |
Ir | Information ratio | -0.15 |
Aprea Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aprea Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aprea Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aprea Therapeutics generated a negative expected return over the last 90 days | |
| Aprea Therapeutics has high historical volatility and very poor performance | |
| Aprea Therapeutics has some characteristics of a very speculative penny stock | |
| Aprea Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (12.96 M) with loss before overhead, payroll, taxes, and interest of (7.91 M). | |
| Aprea Therapeutics currently holds about 39.06 M in cash with (13.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aprea Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hamill John P. of 5700 shares of Aprea Therapeutics at 0.765 subject to Rule 16b-3 |
Aprea Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aprea Stock often depends not only on the future outlook of the current and potential Aprea Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aprea Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.5 M | |
| Cash And Short Term Investments | 22.8 M |
Aprea Therapeutics Fundamentals Growth
Aprea Stock prices reflect investors' perceptions of the future prospects and financial health of Aprea Therapeutics, and Aprea Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aprea Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | (9.59 M) | ||||
| Shares Outstanding | 6.99 M | ||||
| Price To Earning | (9.54) X | ||||
| Price To Book | 0.51 X | ||||
| Price To Sales | 10.75 X | ||||
| Revenue | 1.5 M | ||||
| Gross Profit | (7.91 M) | ||||
| EBITDA | (14.3 M) | ||||
| Net Income | (12.96 M) | ||||
| Cash And Equivalents | 39.06 M | ||||
| Cash Per Share | 1.67 X | ||||
| Total Debt | 4.67 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.45 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (13.56 M) | ||||
| Earnings Per Share | (2.12) X | ||||
| Market Capitalization | 5.25 M | ||||
| Total Asset | 23.98 M | ||||
| Retained Earnings | (321.04 M) | ||||
| Working Capital | 20.22 M | ||||
| Current Asset | 39.28 M | ||||
| Current Liabilities | 5.96 M | ||||
About Aprea Therapeutics Performance
By analyzing Aprea Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Aprea Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aprea Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aprea Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (0.80) | (0.84) | |
| Return On Assets | (0.62) | (0.65) | |
| Return On Equity | (0.77) | (0.81) |
Things to note about Aprea Therapeutics performance evaluation
Checking the ongoing alerts about Aprea Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aprea Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aprea Therapeutics generated a negative expected return over the last 90 days | |
| Aprea Therapeutics has high historical volatility and very poor performance | |
| Aprea Therapeutics has some characteristics of a very speculative penny stock | |
| Aprea Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (12.96 M) with loss before overhead, payroll, taxes, and interest of (7.91 M). | |
| Aprea Therapeutics currently holds about 39.06 M in cash with (13.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aprea Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hamill John P. of 5700 shares of Aprea Therapeutics at 0.765 subject to Rule 16b-3 |
- Analyzing Aprea Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aprea Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aprea Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aprea Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aprea Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aprea Therapeutics' stock. These opinions can provide insight into Aprea Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aprea Stock analysis
When running Aprea Therapeutics' price analysis, check to measure Aprea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aprea Therapeutics is operating at the current time. Most of Aprea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aprea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aprea Therapeutics' price. Additionally, you may evaluate how the addition of Aprea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |